1. Home
  2. EXP vs PCVX Comparison

EXP vs PCVX Comparison

Compare EXP & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Materials Inc

EXP

Eagle Materials Inc

HOLD

Current Price

$216.82

Market Cap

7.0B

Sector

Industrials

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$47.28

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXP
PCVX
Founded
1963
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
7.0B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
EXP
PCVX
Price
$216.82
$47.28
Analyst Decision
Hold
Strong Buy
Analyst Count
9
4
Target Price
$227.11
$88.25
AVG Volume (30 Days)
393.7K
1.4M
Earning Date
05-19-2026
05-07-2026
Dividend Yield
0.49%
N/A
EPS Growth
N/A
N/A
EPS
13.16
N/A
Revenue
$495,023,000.00
N/A
Revenue This Year
$1.97
N/A
Revenue Next Year
$1.95
N/A
P/E Ratio
$16.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$171.99
$29.10
52 Week High
$243.64
$65.00

Technical Indicators

Market Signals
Indicator
EXP
PCVX
Relative Strength Index (RSI) 55.96 41.44
Support Level $202.60 $46.39
Resistance Level $224.61 $49.46
Average True Range (ATR) 6.97 1.94
MACD -0.03 0.03
Stochastic Oscillator 64.92 30.30

Price Performance

Historical Comparison
EXP
PCVX

About EXP Eagle Materials Inc

Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: